Omnicom Media Group India’s Post

ACCESS Health International was pleased to partner with ASK Health Asia on several panes of the Asia #Health and Life Sciences #Innovation and Cooperation Summit which took place this week in #Singapore. It was an honour for me to share the stage with Jeff Weisel, Rosaline Chow Koo and Ritesh Thakkar whom I learned a lot from in terms of solutions to improve financing for healthcare. I was pleased to share more about some of the great work facilitated by the ACCESS Health Team since 2019 on #FinTech for Health. Digital solutions and cross-sectoral collaborations can help address coverage gaps and better respond to the needs of communities to access the care that they need and make that more efficient and affordable for them. #universalhealthcoverage #peoplecentered #globalhealth #digitaltransformation #accesstohealthcare

Peach Health ran its strategic advisory board meetings last week, and the management team (plus one furry guest) held a post meeting dinner to re-visit the findings from the meeting. We split our 8 strategy board members in 3 groups to allow them to cover various topics that matched their strengths. We picked up many valuable insights during the discussions including the few tidbits below: 1. How to attract international digital health partners to Asia: a key parameter that will attract third party digital health / digital therapeutics developers to work with Peach in Asia is to create a hassle free seamless model to get into the Asia healthcare market. In particular any digital development work and other incremental work for the partner needs to be kept to a minimum. 2. Digital health products and path to market: there were a lot of viewpoints on path to market, and the weight of the groups opinion was that a D2C entry would be difficult and we should focus on a medical channel path to market. This is also not without challenges, as shown by companies in the US that have followed this route. 3. Right balance with partners vs internal sources: healthcare is complicated, doing it in multiple Asia countries makes it even more complicated. Building internal capabilities is good, but Peach should explore partnerships to accelerate growth and scaling of the business. Thanks a million for the valuable session strategic advisory board members: Chris Wasden, Alex Waldron, Anne Bell, Dan Millard, Louis Island, Daniel Laverick, Tom Vanmolkot, Derrick Neo Aik Keong #peachhealthasia #digitaltherapeutics #asiahealth

How do we channel the urgency for cross-regional commitment to health in the post-pandemic era? Dr Krishna Reddy Nallamalla, President, Asia, ACCESS Health International will moderate a panel at an event organised by ASK Health Asia titled “2023 Asia Health and Life Sciences Innovation and Cooperation Summit” and will discuss the above question and try to arrive at takeaways for the Asia-Pacific region. The panel Dr Reddy will be moderating will comprise of: Sylvia Varela, Asia Area Vice President at AstraZeneca Diah Satyani Saminarsih, Founder and Chief Executive Officer, Center for Indonesia's Strategic Development Initiatives (CISDI) Naina Subberwal Batra, CEO, AVPN Dr Dinesh Arora, Principal Health Specialist, Asian Development Bank (ADB) Kotaro Tamura, Adjunct Professor, Lee Kuan Yew School of Public Policy; Chairman, Ecosphere This panel discussion is part of a wider topic titled "Market Opportunities for Life Sciences Innovation in Asia" where ACCESS Health International is a Session Partner alongside AstraZeneca. The key discussion points within this topic include cross-regional cooperation in the healthcare sector; market opportunities for life sciences innovation; and the need to address disease burden and patient needs. Please find the link to the summit website in the comments section below. #LifeSciences #HealthcareCooperation #DiseaseBurden #PatientNeeds #HealthcareSummit #AsiaHealth #HealthInnovation #HealthcarePartnership #GlobalHealth #HealthLeaders

Join us this July to learn from experts around the world on the latest in #clinicaltrials! 💡 Day 1 Speaker Highlights 💡 ➡️ Keynote Speakers Our keynote speakers will speak on how clinical trials is transforming healthcare delivery, such as during the COVID-19 pandemic. These presentations will be followed by an engaging panel that will explore the value proposition of clinical trials from the patient's, healthcare professionals and industry perspective. ➡️ Clinical Trials for Health Outcomes and its Impact on Healthcare Esteemed health economists will explain the key role of Healthcare Economics and Outcomes Research (HEOR) in guiding clinical trials towards the cost-efficient use of resources and examine the overall impact on population health when it comes to exploring new or novel healthcare interventions. ➡️ Patient Advocacy Groups, Community Involvement and Collaboration in Advancing Clinical Research Patient advocacy reps from the community will discuss how a deeper understanding of patient needs has potential to sharpen research relevance and accelerate the development of innovative therapies for better healthcare. 💡 Day 2 Speaker Highlights 💡 ➡️ Unveiling Diverse Clinical Trial Landscapes Across Countries Panellists will discuss the latest clinical trial developments from around the world, as well as explore ways to improve collaboration across borders to advance clinical research. ➡️ Challenges and Opportunities for Biotechs to Conduct Clinical Trials in Singapore Panellists will explore the unique challenges and opportunities in conducting clinical trials in Singapore. From regulatory considerations to infrastructure development and funding, hear from speakers on how they are navigating the local clinical trial landscape. ➡️ Innovations in Data-Driven Research: Shaping Tomorrow's Discoveries In this digital age, our panel speakers will uncover how data-driven research, with stringent data governance in place, is driving innovation and shaping future discoveries. 🙋♂️ 🙋♀️ Sign-up for this conference to learn from the best and keep the conversations going at this excellent opportunity for knowledge exchange and networking. 🗓️ 30 to 31 July 2024 📍 Raffles City Convention Centre 📣 🐥 Early bird tickets available until 31 May 2024. 👉 Register now at https://for.sg/symposiumli Swipe through to find out more about the discussions in store for Day 1 and Day 2! For more information, visit https://for.sg/symposiumli #SCRIClinicalTrialsSymposium2024 #TransformingTomorrowsHealth #ClinicalTrials

Thanks, Hao Tran and Vietcetera Media, for sharing an enriching conversation with Dr. Dilshaad Ali, Group CEO of Hoan My Medical Corporation, on "Transforming Healthcare in Vietnam." My takeaways from the conversation: 1. Mindset Shift. The population in Vietnam has gradually shifted their mindset towards wellness and health, with an emphasis on prevention rather than treatment. This includes mental and beauty wellness. 2. Hoan My Ecosystem. Hoan My has an end-to-end system that emphasizes accessibility through digital platforms, such as remote healthcare for the elderly and wellness focus. The multiple platforms available include Hoan My (Rising middle class), Thuan My (Affordable class), Hanh Phuc (Mother & Child, moving into General practice), Tien Phong Lab (Diagnostic Labs), Danh Y (Digital platform), and HM Academy (Training & Education). 3. Future Talent. Hoan My emphasizes a team mindset of talent acquisition that includes multicultural experts from different backgrounds, including young Vietnamese. This will support the future growth of the Vietnamese healthcare system. 4. Accessible and Affordable Care for the Future. As the most dominant private healthcare provider in the market, Hoan My aims to continue having that leadership in the market. The goal is to offer healthcare as a responsible healthcare provider in the private sector by continuously making healthcare accessible and affordable for every Vietnamese while also maintaining an agile and flexible approach based on how the country and demographics will move into the future. I am thrilled to be a part of Hoan My's journey, contributing to the development of Vietnam's healthcare sector. To watch the full conversation, check out the link below: https://lnkd.in/gzPqEhsK

Register below to hear about the potential of predictive AI to transform urban population health and advance health equity. Especially excited to discuss how to harness insights from data rich cities to scale innovation for impact in LMICs!

Health systems are faced with many choices when it comes to population health. Increasing costs for sick care, decisions on which innovations they can approve and afford, and evolving medical practices in both prevention and treatment which can challenge existing regulatory norms. In the latest episode of Digital Health Today Asia Pacific Edition, Antonio Estrella sits down with Clive Tan, a Founding Member of Precision Public Health Asia Society to discuss how their work is serving to harmonise the decisions the ASEAN region is making to improve population health Topics include: - The definition of "position public health" and how it has evolved over the past decade. - Singapore's HealthierSG programmeHow economic growth in ASEAN countries is impacting public health priorities. - Main takeaways from the leadership forum in terms of country development and collaboration opportunities. - The regulatory opportunities discussed at the leadership forum.and much more! Listen now: https://lnkd.in/eChEaD3K Amalgam Rx LSI - Life Science Intelligence™, Bayer G4A, Lindus Health Health Podcast Network, Novartis, UnderwriteMe, PT Global Urban Esensial, The N.1 Institute for Health Bristol Myers Squibb, Praava Health, Halodoc, Holmusk, AMILI , Ujala Cygnus, AXA, Ageing Asia , MyDoc | Simplify Healthcare, Roche, Health Catalyst, Qure.ai #DigitalHealth #DHT #AsiaPacific #ASEAN

RSVP to our panel cohosted with Eli Lilly and Company and EVA pharma in #Geneva #Switzerland during World Health Organization #WHA77 #WorldHealthAssembly on how #partnerships have spurred #innovation in #manufacturing for #NCD products and accelerated access, affordability, and overall quality of medicines. This program will emphasize the importance of global governments applying enabling policies to streamline regulatory pathways, develop healthy markets, and bolster health system capacity in order to deliver on the goal of improving access to life-saving medicines in low and middle income countries. Speakers include: Robert LLoyd, Vice President Lilly International’s 30x30 Social Impact, Eli Lilly and Company; Dr. Sylvia Vito, Africa Head, Sub-Sahara Africa and Frontier Markets, EVA Pharma; Javier Guzman, Director, Global Health Policy and Senior Policy Fellow, Center for Global Development; Dr. Catherine Kanari, Universal Health Coverage Lead, Amref Health Innovations, Amref Health Africa / Afrique de l'Ouest; and Dr. Raji Tajudeen, Acting Deputy Director-General, Africa CDC

AHLSICS 2023: Pioneering Health and Life Sciences Innovation and Cooperation in Asia   Exciting insights on the future of healthcare! The 2023 Asia Health and Life Sciences Innovation and Cooperation Summit (AHLSICS) recently concluded in Singapore. Hosted by ASK Health Asia, SingHealth Duke-NUS Global Health Institute, and in collaboration with the World Economic Forum. The AHLSICS brought together close to 90 health system leaders, multi-lateral organization representatives, policy experts, academic leaders, and ecosystem partners from nearly twenty countries and regions in Asia.   Over the course of the two days, we covered 8 topics under health and life sciences innovation, facilitated and curated 12 engaging panel discussions, 8 innovative showcases, 2 lunch talks and an inspiring Singapore Networking Dinner.   ◉ Key highlights:   - Cross-Regional Collaboration - Innovation and Technology - Regulatory Cooperation - Health Financing Innovation - Commercialization Cooperation - Life Sciences Capital Market and Investment   ◉ Special thanks to our partners:   - Strategic partner: SingHealth Duke-NUS Global Health Institute, in collaboration with World Economic Forum   - Partner: AstraZeneca, Haitong International Securities Group Limited, Microsoft Cloud, Ubang, GenScript, United Imaging Healthcare, Russell Reynolds Associates, CICC, ACCESS Health International, AVPN, ISPOR Singapore, ISPOR—The Professional Society for Health Economics and Outcomes Research, SGX Group   Media Partner: Caixin Global, TechNode.com, PharmCube   Learn More: www.askhealthasia.com / www.askhealth.com.cn   #Healthcare #Innovation #LifeSciences #AsiaHealth #Collaboration #HealthTech #Summit #AHLSICS #CrossRegionalCooperation   ASK Health Asia is an Asia based think tank, consultancy, and venture builder in healthcare. Headquartered in Singapore, ASK Health Asia has extensive experience and operations in Southeast Asia, Mainland China, and Macau, with close partnership in India, Japan, Korea, Australia, and Middle East. ASK Health is a premier catalyst for health systems transformation in Asia. Through in-depth research, consultancy, platform development, solution co-creation and resource connection, we work closely with development partner, governments, and industry leaders to jointly capture growth opportunities from new health policies and provide innovative solutions to the economies across Asia.  

As we bring 2023 to a close, I reflect on the progress and momentum the Global Health Unit (GHU) team as achieved over the past twelve months, helping to deliver on Sanofi’s social impact strategy. Over the course of 2023, with our partners, we were able to successfully bring quality, affordable treatments to ~240,000 patients across 31 countries.   Access to sustainable healthcare is increasingly more complex, requiring us to think outside the box by adopting innovative access models and embracing multi sectoral partnerships to have a lasting impact and address disparities in low- to middle-income countries. To create sustainable health care systems, it is imperative we work together. Some of the GHU highlights for 2023 include:   Engaging with local partners, we have supported over 39 training programs across 24 countries in the past year, with many more preparing to launch in 2024. We are delivering on our aim to drive capacity building initiatives that will result in better diagnosis and treatment of patients suffering from non-communicable diseases in the most vulnerable communities. We have helped train over 4200 HCPS and HCWs. We celebrated the first delivery from our Impact brand portfolio to Djibouti in Q4, followed by Tanzania and several other countries by year end. We will continue to bring our dedicated, not-for-profit, Impact brand products to our GHU countries in 2024. I was fortunate to attend and participate in several Global Health panel discussions this year, including events at UNGA, the World Health Summit, and the Impact Europe Impact Week. There were common themes central in many of these discussions including the need for prioritization, collaboration and cooperation to overcome global health challenges. Also, the importance of multi-sectoral engagement, particularly with local agencies and partners who have the greatest understanding of the specific community needs, is critical for sustainable impact. Through our Impact Fund, we are continuing to invest in local entrepreneurs to support the scale and growth of businesses that can help strengthen the communities where they operate. 2023 was an impressive year and we are motivated to keep the momentum going. A BIG THANK YOU to our partners, it would not have been possible without you! https://lnkd.in/eNpFjm4T